Pieter Slegers — Why you should invest in boring companies (#QualityTuesday)
Three reasons boring wins — essential, unreplaceable, predictable — plus Greenblatt's Magic Formula at 33% a year, Chris Mayer's 100 Baggers, and an Intuitive Surgical pitch priced at 47.8x.
One-line take: the shortest issue in the February run and the clearest statement of the house test. Boring companies outperform for three reasons — "They are essential / They have no replacement / They generate a stable and predictable cash flow" — which is the toll-bridge screen expressed as a checklist rather than a metaphor. The temperament line is the memorable one: "Investing is simple, but not easy. It should be very boring. Like watching paint dry or grass grow. If you want excitement, you should go to Las Vegas." Two pieces of reading: Joel Greenblatt's The Little Book That Still Beats the Market (the Magic Formula returned "33% (!) per year" between 1985 and 2005) and Chris Mayer's 100 Baggers, with a link to a prior Compounding Quality interview. The stock pitch is Intuitive Surgical, and it is the one that does not fit the frame: net cash, a 28.4% net margin, an 18.4% ROIC and +26.6% a year since 2001 — but a 47.8x forward PE, in an issue that spends four sections arguing for cheap, dull businesses. No valuation verdict is offered.
1. Stocks & names mentioned
One name in this issue. Intuitive Surgical is Positive — it is presented as a #QualityTuesday stock pitch with the moat and returns argued, though no valuation judgement is given and the 47.8x forward multiple is disclosed without comment. Research legend: QT Qualtrim · SA Seeking Alpha · STK Stock Analysis. Written post with no timestamps — the At link opens the article.
| Ticker | Name | Research | View | What he said | At |
|---|
| ISRG | Intuitive Surgical | QT · SA · STK · FA | Positive | #QualityTuesday stock pitch. "Intuitive Surgical makes money by selling da Vinci surgical robots. It generates recurring revenue from instruments, accessories, and service contracts used in every procedure." The moat is the razor-and-blades lock-in: "every time a hospital buys a robotic surgery system, ISRG gets a new customer for life. And hospitals worldwide are buying these systems faster than ever." Described as "a quality healthcare tech leader with a strong moat and high switching costs." The disclosed numbers: net cash position, net profit margin 28.4%, ROIC 18.4%, forward P/E 47.8x, and a +26.6% CAGR since 2001. No entry price, target multiple or valuation verdict is given. | read ↗ |
Stance = how the name is framed in this post. The archive's earlier mention of Intuitive Surgical (18 August 2026) is a guest's reference to it as one of David Gardner's 100-baggers; this is the first time Compounding Quality itself pitches the business. Joel Greenblatt and Chris Mayer are cited as authors, not as investable names.
2. Talking points
1. Boring is beautiful — the three-part test
- "Do you know why boring companies outperform the market? There are three main reasons: They are essential / They have no replacement / They generate a stable and predictable cash flow."
- Read as a screen rather than an aphorism, this is the toll-bridge test in plain form: demand that does not depend on a decision, no substitute at any price, and cash that arrives on a schedule. Every February Best Buy — MSCI, S&P Global, KKR, Adyen, Pool — passes all three.
- "That's why quality investors tend to outperform the markets."
2. Greenblatt and the Magic Formula
- "Between 1985 and 2005, his Magic Formula generated a return of 33% (!) per year." Note the figure differs from the "+40% (!) for over 20 years" cited five days earlier on 12 February — the fund's return versus the formula's backtest, quoted interchangeably.
- The Little Book That Still Beats the Market is "pure gold," with a three-page summary linked. The formula itself — rank on earnings yield and return on capital — is not spelled out in this issue.
3. The temperament line
- "Investing is simple, but not easy. It should be very boring. Like watching paint dry or grass grow. If you want excitement, you should go to Las Vegas."
- The same idea Buffett supplies elsewhere in the archive ("good investing is like watching paint dry"), used here as the behavioural counterpart to the business test: a boring business only compounds for an investor who can tolerate a boring holding.
4. Chris Mayer and 100 Baggers
- "He wrote the excellent book 100 Baggers," with a link to a prior Compounding Quality interview.
- Mayer's framework recurs across the archive as the twin-engine decomposition — a stock rises on earnings growth multiplied by multiple change — used in July 2026 on Caterpillar and Nvidia.
5. The Intuitive Surgical pitch, and the tension in it
- The business model is the classic installed-base annuity: sell the robot once, then earn on the instruments, accessories and service used in every subsequent procedure. "ISRG gets a new customer for life."
- The quality metrics are strong and consistent with the house screen: net cash, a 28.4% net margin, an 18.4% ROIC, and a 26.6% annual return since 2001.
- The valuation is stated and left alone: 47.8x forward earnings. In an issue arguing for essential, unreplaceable, predictable businesses, the pitch is a business that passes every quality test and is priced accordingly — the reader is given the multiple and no verdict on it.
3. In plain English
A jargon-free summary of the thesis behind the argued name. (Renders on the name's consolidated page.)
ISRG — Intuitive Surgical Positive
Intuitive Surgical makes the da Vinci robot — the machine a surgeon sits at to operate through tiny incisions instead of by hand. The robot itself is only the entry point. Every operation performed on it uses instruments and accessories that wear out and must be replaced, and every machine needs a service contract. So the money keeps arriving long after the sale, in proportion to how much the hospital uses it.
That is why Slegers calls a robot sale "a new customer for life." Surgeons train for years on a specific system, hospitals write it into their protocols, and switching means retraining an entire theatre team — the switching costs are practical rather than contractual, which is the more durable kind. The financials back the description: no net debt, 28.4% of revenue converted to profit, an 18.4% return on the capital employed, and a 26.6% annual return to shareholders since 2001.
The number to weigh against all of that is the price: 47.8 times next year's expected earnings. Slegers gives it without comment. Read against the rest of the issue — four sections arguing for dull, essential, cheaply-bought businesses — this is a quality pitch, not a valuation one.
Summary derived from the archived Compounding Quality post (text in transcript.txt) for personal study. Not investment advice. © Compounding Quality / Pieter Slegers for source material.